Health care stocks were declining late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling 1.1%.
The iShares Biotechnology ETF (IBB) dropped 1.3%.
In corporate news, Inogen (INGN) shares rose nearly 6% after the company said Monday it received US Food and Drug Administration clearance for its Simeox 200 airway clearance device, which is designed to help people with chronic respiratory diseases manage bronchial drainage.
Rocket Pharmaceuticals' (RCKT) pipeline development together with its in-house manufacturing capacity are expected to support "strong" long-term growth potential for the company, Wedbush said in a note. Wedbush initiated Rocket with an outperform rating and a $32 price target. Rocket shares added 2.4%.
Marinus Pharmaceuticals (MRNS) shares surged 43% after the company said it signed a deal under which Immedica Pharma will buy all of its issued and outstanding stock for $0.55 a share.
Emergent BioSolutions (EBS) shares jumped 12% after HC Wainwright started coverage of the stock with a buy rating and a $15 price target.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。